PFEpartnership
Pfizer announced an exclusive licensing agreement with Starna Therapeutics worth up to $2.63 billion to develop in vivo CAR-T cell therapies for autoimmune diseases.
Benzinga
2 stories shown
Pfizer announced an exclusive licensing agreement with Starna Therapeutics worth up to $2.63 billion to develop in vivo CAR-T cell therapies for autoimmune diseases.
Pfizer is discontinuing the sale of its hormone replacement therapy Premarin in Canada following an internal review.